Dicerna Pharmaceuticals (NASDAQ:DRNA) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.15), Fidelity Earnings reports. Dicerna Pharmaceuticals had a negative return on equity of 50.30% and a negative net margin of 737.93%. The company had revenue of $8.04 million for the quarter, compared to analysts’ expectations of $11.70 million.
Shares of NASDAQ DRNA traded up $0.09 during midday trading on Friday, hitting $17.69. The company’s stock had a trading volume of 824,800 shares, compared to its average volume of 465,156. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.65. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -14.74 and a beta of 2.29. The business’s fifty day simple moving average is $15.51 and its two-hundred day simple moving average is $14.24. Dicerna Pharmaceuticals has a 1 year low of $9.31 and a 1 year high of $18.39.
In other news, CFO John B. Green sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of $18.00, for a total transaction of $225,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider James B. Weissman sold 14,680 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $13.07, for a total transaction of $191,867.60. Following the transaction, the insider now owns 9,800 shares in the company, valued at $128,086. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,180 shares of company stock worth $686,868. Insiders own 21.28% of the company’s stock.
Several research analysts have recently commented on DRNA shares. ValuEngine raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. BidaskClub raised shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. HC Wainwright set a $22.00 price objective on shares of Dicerna Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 26th. Finally, Leerink Swann raised their price objective on shares of Dicerna Pharmaceuticals from $22.00 to $26.00 in a research note on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Dicerna Pharmaceuticals has an average rating of “Buy” and a consensus price target of $22.50.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Further Reading: Strangles
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.